BURZYNSKI RESEARCH INSTITUTE INC Overview
Industry: Biotechnology
Sector: Healthcare
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
BURZYNSKI RESEARCH INSTITUTE INC is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review BURZYNSKI RESEARCH INSTITUTE INC in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
BURZYNSKI RESEARCH INSTITUTE INC Competitors
BURZYNSKI RESEARCH INSTITUTE INC operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans